Each month, subscribers to The Formulary® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.
Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The May 2002 Formulary monograph topics are 90Y ibritumomab tiuxetan, inerferon beta-1a, tiotropium, rifaximin, and eplerenone. The DUE is on pegfilgrastim.
Get full access to this article
View all access options for this article.
References
1.
FDA Advisory Committee recommends approval of Amgen's Kineret for the treatment of rheumatoid arthritis.Amgen, Inc.; August 16, 2001. www.amgen.com. Accessed on August 16, 2001.
2.
HebelS., Ed. Drug Facts and Comparisons: Clinisphere Edition.St. Louis, MO: Facts & Comparisons, Inc.; 2002.
3.
Kineret package literature.Amgen, Inc.; November 2001.
4.
ArendW.P.Cytokine imbalance in the pathogenesis of rheumatoid arthritis: The role of interleukin-1 receptor antagonist.Sem Arthritis Rheum.2001; 30(5 suppl 2): 1–6.
5.
van den BergW.B.Uncoupling of inflammatory and destructive mechanisms in arthritis.Semin Arthritis Rheum.2001; 30(5 suppl 2): 7–16.
6.
SchiffM.H.Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis.Ann Rheum Dis.2000; 59(suppl 1): i103–8.
7.
van den BergW.B.Joint inflammation and cartilage destruction may occur uncoupled.Springer Semin Immunopathol.1998; 20: 149–64.
8.
MainiR.N., TaylorP.C.Anti-cytokine therapy for rheumatoid arthritis.Annu Rev Med.2000; 51: 207–29.
9.
Amgen, Inc.Kineret (anakinra) (recombinant methionyl human interleukin-1 receptor antagonist). FDA Arthritis Drugs Advisory Committee Briefing Package.Amgen, Inc. July 17, 2001.
10.
CampionG.V.Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis.Arthritis Rheum.1996; 39(7): 1092–101.
11.
EdwardsC.K.Selective inhibition of IL-1B induced proinflammatory gene expression by recombinant IL-1 receptor antagonist (IL-1RA; anakinra) in human whole blood cultures: Contrast to other anti-inflammatory agents [abstract].Arthritis Rheum.2001; 44(9 suppl): 1470.
12.
ZhuL.Efficacy of treatment with anakinra in combination with other therapeutics in rat models of arthritis [abstract].Arthritis Rheum.2001; 44(9 suppl): 1131.
13.
QianX.Synergistic effect of IL1RA and etanercept on inhibition of human chondrocytes responses to cytokines derived from anti-CE3/CD28 stimulated human PBMC [abstract].Arthritis Rheum.2001; 44(9 suppl): 337.
14.
DinarelloC.A.The role of the interleukin-1 - receptor antagonist in blocking inflammation mediated by interleukin-1.N Engl J Med.2000; 343(10): 732–4.
15.
JouvenneP.Elevated levels of soluble interleukin-1 receptor type II and interluekin-1 receptor antagonist in patients with chronic arthritis: Correlations with markers of inflammation and joint destruction.Arthritis Rheum.1998; 41(6): 1083–9.
16.
GranowitzE.V.Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans.Cytokine.1992; 4(5): 353–60.
17.
YangB.B.Population pharmacokinetics of recombinant interluekin-1 receptor antagonist (anakinra) in subjects with rheumatoid arthritis (RA) [abstract]. American College of Rheumatology 64th Annual Scientific Meeting. Philadelphia, PA; 2000, 519.
18.
FelsonD.T.The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials.Arthritis Rheum.1993; 36: 729–40.
19.
WernickR.Update in rheumatology.Ann Intern Med.2000; 132: 125–33.
20.
Clinical review.Biologic Licensing Application: STN 103950, anakinra for use in the treatment of rheumatoid arthritis. FDA Arthritis Drugs Advisory Committee. Center for Drug Evaluation and Research.Food and Drug Administration. July 9, 2001.
21.
BresnihanB.Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.Arthritis Rheum.1998; 41(12): 2196–204.
22.
BresnihanB.The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis.Sem Arthritis Rheum.2001; 30(5 suppl 2): 17–20.
23.
JiangY.A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis.Arthritis Rheum.2000; 43(5): 1001–9.
24.
BresnihanB.Increases in productivity after six and twelve months of anakinra treatment in patients with rheumatoid arthritis [abstract].Arthritis Rheum.2001; 44(9 suppl): 148.
25.
GenantH.K.Treatment with anakinra reduces the rate of joint destruction and shows accelerated benefit in the second 6 months of treatment for patients with rheumatoid arthritis [abstract]. American College of Rheumatology 64th Annual Scientific Meeting. Philadelphia, PA; 2000, 1332.
26.
BresnihanB.Anakinra reduces the rate of joint destruction after 1 year of treatment in a randomized controlled cohort of patients with rheumatoid arthritis [abstract]. American College of Rheumatology 64th Annual Scientific Meeting. Philadelphia, PA; 2000, 1333.
27.
WattI., CobbyM.Treatment of rheumatoid arthritis patients with interleukin-1 receptor antagonist: Radiologic assessment.Semin Arthritis Rheum.2001; 30(5 suppl 2): 21–5.
28.
GenantH.K.Interleukin-1 receptor antagonist treatment of rheumatoid arthritis patients: Radiologic progression and correlation of Genant/Sharp and Larsen scoring methods.Semin Arthritis Rheum.2001; 30(5 suppl 2): 26–32.
29.
CohenS.B.The impact of anakinra therapy on patient-centered outcomes in rheumatoid arthritis [abstract].Arthritis Rheum.2001; 44(9 suppl): 149.
30.
CohenS.Treatment of interleukin-1 receptor antagonist in combination with methotrexate (MTX) in rheumatoid arthritis (RA) patients.Arthritis Rheum.1999; 42(9 suppl): 1217.
31.
CohenS.B.IL1-ra improves health-related quality of life as measured by the health assessment questionnaire [abstract]. American College of Rheumatology 64th Annual Scientific Meeting. Philadelphia, PA: 2000: 1331.
32.
CohenS.B.Characterizing the health-related quality of life effects of IL1-ra therapy as measured by the health assessment questionnaire [abstract]. American College of Rheumatology 64th Annual Scientific Meeting. Philadelphia, PA; 2000, 485.
33.
CohenS.B.Anakinra (recombinant interleukin-1 receptor antagonist): A large, placebo-controlled efficacy trial of anakinra in patients with erosive rheumatoid arthritis disease [abstract].Arthritis Rheum2001; 44(9 suppl): LB-1.
34.
SchiffM.H.Safety of combination therapy with anakinra and etanercept in patients with rheumatoid arthritis [abstract].Arthritis Rheum.2001; 44(9 suppl): 157.
35.
FleischmanR.A safety trial of anakinra: Recombinant interleukin-1 receptor antagonist (IL-1RA), in a large, placebo-controlled heterogeneous population of patients with rheumatoid arthritis [abstract].Arthritis Rheum.2001; 44(9 suppl): 190.
36.
MartinS.W.Pharmacokinetics (PK) of neither anakinra (interleukin-1 receptor antagonist, IL-1ra) nor pegylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) were altered after combination treatment in subjects with rheumatoid arthritis (RA) [abstract].Arthritis Rheum.2001; 44(9 suppl): 159.
